Cutaneous Melanoma Risk and Menopausal Hormone Therapy
Associations between estrogen therapy, estrogen-progestin therapy, and cutaneous melanoma risk were estimated.
Associations between estrogen therapy, estrogen-progestin therapy, and cutaneous melanoma risk were estimated.
Women of reproductive age who currently use hormonal contraceptives are at higher risk for developing glaucoma.
Only 29% of children and adolescents with gender dysphoria receive a gender dysphoria-related diagnosis, and 25% are prescribed gender-affirming hormonal treatment.
The researchers studied links between gender-affirming surgeries and mental health outcomes, including psychological distress, substance use, and suicide risk.
A team of researchers assessed laboratory parameters in patients undergoing gender-affirming hormone therapy.
Within two to four months of starting gender-affirming hormone therapy,, transfeminine adults have lower mean systolic blood pressure and transmasculine adults have higher mean systolic blood pressure.
Higher rates of smoking, lower rates of lung cancer screening, and more diagnoses of asthma and COPD have been seen in transgender vs cisgender individuals.
Risk-reducing bilateral salpingo-oophorectomy can reduce the risk of ovarian cancer for BRCA1 and BRCA2 carriers, but the surgery leads to early menopause. Little is known how undergoing the surgery will affect cognition in women who undergo the procedure. In this featured study, researchers share new findings.
Excessive urination at night, or nocturia, is not uncommon in postmenopausal women. There are a number of treatment options available but with varying degrees of success.
In this clinical practice review correspondence recently published in the Journal of Clinical Endocrine and Metabolism, physicians challenge some of the standard prescribing guidance for gender affirming hormone therapy.